Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Through the acquisition, Boehringer expands its immuno-oncology portfolio and a proprietary therapy platform that uses live bacteria to deliver immune-modulating proteins to cancer cells and tumor micro-environments.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Large molecule
Partner/Sponsor/Collaborator: Boehringer Ingelheim GmbH
Deal Size: $509.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition November 22, 2023
Details:
T3 Pharma will use the funds primarily to progress its lead candidate, T3P-Y058-739, through clinical studies. The Phase 1/2 clinical study in solid tumors is planned to start in early 2021.
Lead Product(s): T3P-Y058-739
Therapeutic Area: Oncology Product Name: T3P-Y058-739
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Boehringer Ingelheim GmbH
Deal Size: $27.4 million Upfront Cash: Undisclosed
Deal Type: Financing July 22, 2020